These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 717574)

  • 21. Experience with depot neuroleptics in ambulatory practice.
    Fiolet J
    Acta Psychiatr Belg; 1981; 81(2):182-8. PubMed ID: 6117188
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patients at risk of developing severe side effects from depot fluphenazine treatment.
    Blum A
    Am J Psychiatry; 1980 Feb; 137(2):254-5. PubMed ID: 7352591
    [No Abstract]   [Full Text] [Related]  

  • 23. Comparison of antipsychotic depot injections in the maintenance treatment of schizophrenia.
    Carney MW; Sheffield BF
    Br J Psychiatry; 1976 Nov; 129():476-81. PubMed ID: 990663
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relation of plasma fluphenazine levels to treatment response and extrapyramidal side effects in first-episode schizophrenic patients.
    Koreen AR; Lieberman J; Alvir J; Chakos M; Loebel A; Cooper T; Kane J
    Am J Psychiatry; 1994 Jan; 151(1):35-9. PubMed ID: 8267132
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Iatrogenic morbidity in patients taking depot fluphenazine.
    Jose C; Mallya A; Mehta D; Evenson R; Holland R
    Am J Psychiatry; 1979 Jul; 136(7):976-7. PubMed ID: 453363
    [No Abstract]   [Full Text] [Related]  

  • 26. Depressive and extrapyramidal symptoms and clinical effects: a trial of fluphenazine versus flupenthixol in maintenance of schizophrenic out-patients.
    Knights A; Okasha MS; Salih MA; Hirsch SR
    Br J Psychiatry; 1979 Dec; 135():515-23. PubMed ID: 394794
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Side effects during long-term treatment with depot antipsychotic medication.
    Cookson JC
    Clin Neuropharmacol; 1991; 14 Suppl 2():S24-30; discussion S30-2. PubMed ID: 1751940
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Incidence and correlates of acute extrapyramidal symptoms in first episode of schizophrenia.
    Chakos MH; Mayerhoff DI; Loebel AD; Alvir JM; Lieberman JA
    Psychopharmacol Bull; 1992; 28(1):81-6. PubMed ID: 1609046
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Double-blind comparison of haloperidol decanoate and fluphenazine decanoate effectiveness, side-effects, dosage and serum levels during a six months' treatment for relapse prevention.
    Kissling W; Möller HJ; Walter K; Wittmann B; Krueger R; Trenk D
    Pharmacopsychiatry; 1985 May; 18(3):240-5. PubMed ID: 4011672
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fluphenazine dose, clinical response, and extrapyramidal symptoms during acute treatment.
    Levinson DF; Simpson GM; Singh H; Yadalam K; Jain A; Stephanos MJ; Silver P
    Arch Gen Psychiatry; 1990 Aug; 47(8):761-8. PubMed ID: 2378547
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasma levels of fluphenazine in patients receiving fluphenazine decanoate. Relationship to clinical response.
    Marder SR; Midha KK; Van Putten T; Aravagiri M; Hawes EM; Hubbard JW; McKay G; Mintz J
    Br J Psychiatry; 1991 May; 158():658-65. PubMed ID: 1860020
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The initiation of long-term pharmacotherapy in schizophrenia: dosage and side effect comparisons between oral and depot fluphenazine.
    Schooler NR; Levine J
    Pharmakopsychiatr Neuropsychopharmakol; 1976 Jul; 9(4):159-69. PubMed ID: 790413
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fluphenazine enanthate in the outpatient treatment of late paraphrenia.
    Raskind M; Alvarez C; Herlin S
    J Am Geriatr Soc; 1979 Oct; 27(10):459-63. PubMed ID: 469146
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low neuroleptic serum levels in patients receiving fluphenazine decanoate.
    Tune LE; Creese I; Coyle JT; Pearlson G; Snyder SH
    Am J Psychiatry; 1980 Jan; 137(1):80-2. PubMed ID: 6101523
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Course of psychopathologic and extrapyramidal motor symptoms during long-term treatment of schizophrenic patients with psycholeptic drugs (author's transl)].
    Schilkrut R; Duran E; Haverbeck C; Katz I; Vidal P
    Arzneimittelforschung; 1978; 28(9):1494-5. PubMed ID: 38807
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The use of fluphenazine enanthate in psychotic patients.
    Routsonis KG; Photiadis H
    Curr Ther Res Clin Exp; 1973 Mar; 15(3):92-6. PubMed ID: 4196232
    [No Abstract]   [Full Text] [Related]  

  • 37. Fluphenazine enanthate and fluphenazine decanoate: a comparative study in chronic schizophrenic outpatients.
    Keskiner A; Itil TM; Holden JM
    Psychosomatics; 1969; 10(1):42-5. PubMed ID: 5780681
    [No Abstract]   [Full Text] [Related]  

  • 38. Ten year outcomes of outpatients with schizophrenia on conventional depot antipsychotics: a systematic chart review.
    Uchida T; Suzuki T; Sakurai H; Tsutsumi C; Den R; Mimura M; Uchida H
    Int Clin Psychopharmacol; 2013 Sep; 28(5):261-6. PubMed ID: 23820334
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Movement disorders in patients treated with long-acting injectable antipsychotic drugs.
    Bransgrove LL; Kelly MW
    Am J Hosp Pharm; 1994 Apr; 51(7):895-9. PubMed ID: 7912473
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A depot neuroleptic withdrawal study neurological effects.
    Wistedt B; Wiles D; Jørgensen A
    Psychopharmacology (Berl); 1983; 80(2):101-5. PubMed ID: 6136059
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.